Novavax | NVAX - Cash And Equivalent

Stock Price
8.45
Daily Change
-0.50 -5.59%
Monthly
-16.42%
Yearly
20.71%
Q1 Forecast
8.20

Novavax reported $240.63M in Cash and Equivalent for its fiscal quarter ending in December of 2025.





Cash And Equivalent Change Date
Adma Biologics USD 87.63M 26.24M Dec/2025
Agenus USD 3.46M 6.08M Sep/2025
AstraZeneca USD 8.14B 1.08B Sep/2025
BioCryst Pharmaceuticals USD 335.91M 251.83M Dec/2025
Cassava Sciences USD 106.08M 6.3M Sep/2025
Geron USD 79.44M 553K Dec/2025
GlaxoSmithKline GBP 3.3B 303M Sep/2025
MannKind USD 74.88M 52.51M Dec/2025
Merck USD 18.17B 10.16B Sep/2025
Minerva Neurosciences USD 82.3M 70.02M Dec/2025
Moderna USD 2.6B 1.46B Dec/2025
Novartis USD 9.56B 2.9B Sep/2025
Novavax USD 240.63M 27.39M Dec/2025
Pfizer USD 1.34B 295M Sep/2025
Sanofi EUR 7.66B 1.25B Dec/2025
Sarepta Therapeutics USD 801.28M 188.2M Dec/2025
TG Therapeutics USD 199.51M 21.2M Dec/2025